United States - English - NLM (National Library of Medicine)

pharmaceutical associates, inc. - sodium citrate (unii: 1q73q2julr) (anhydrous citric acid - unii:xf417d3psl), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium citrate 500 mg in 5 ml - sodium citrate and citric acid oral solution usp is an effective alkalinizing agent. it is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. this product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively. sodium citrate and citric acid oral solution usp is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage. this product is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. patients on sodium-restricted diets or with s

United States - English - NLM (National Library of Medicine)

cardinal health - sodium citrate, unspecified form (unii: 1q73q2julr) (anhydrous citric acid - unii:xf417d3psl), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium citrate 500 mg in 5 ml - sodium citrate and citric acid oral solution usp is an effective alkalinizing agent. it is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. this product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively. sodium citrate and citric acid oral solution usp is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage. this product is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. patients on sodium-restricted diets or with s

United States - English - NLM (National Library of Medicine)

atlantic biologicals corp. - sodium citrate (unii: 1q73q2julr) (anhydrous citric acid - unii:xf417d3psl), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium citrate 500 mg in 5 ml - sodium citrate and citric acid oral solution usp is an effective alkalinizing agent. it is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. this product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively. sodium citrate and citric acid oral solution usp is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage. this product is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. patients on sodium-restricted diets or with s

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - glycine; citric acid monohydrate; glucose; potassium citrate; potassium phosphate monobasic; sodium chloride - oral solution/suspension - glycine amino acid-glycine active 38.56 g/l; citric acid monohydrate acid-general active 3.28 g/l; glucose carbohydrate active 278.75 g/l; potassium citrate mineral-potassium active 0.75 g/l; potassium phosphate monobasic mineral-potassium active 25.53 g/l; sodium chloride mineral-sodium-salt active 53.44 g/l - nutrition & metabolism - calf | cat | dog | horse foal | lamb | pigs | sheep ewe (female) | beef calf | bitch | boar | bovine | calf - poddy | calf - pre - bought in - first feed | debilitating viral disease | dehydration | diarrhoea | electrolyte replacement | pregnancy toxaemia | rehydration | scours | absorptive | acute diarrhoea | acute intestinal catarrh | avian blackhead | bacterial enteritis | blackhead | chronic diarrhoea | coccidiosis | dietary factors | dietary upset | enteritis | feed conversion | flatulance | fluid loss | gastro-intestinal | gram negative bacteria | growth rate | k88+ serotypes of e.coli | nesting diarrhoea | non-specific irritants | poisoning | postweaning scours | prophylactic | scours | selenium responsive scours | streptomycin sensitive bacteri | sulphadiazine sensitive bacter | sulphonamide sensitive bacteri | trichomoniasis | trimethoprim sensitive bacteri | white scours

United States - English - NLM (National Library of Medicine)

haemonetics corporation - citric acid monohydrate (unii: 2968phw8qp) (anhydrous citric acid - unii:xf417d3psl), trisodium citrate dihydrate (unii: b22547b95k) (anhydrous citric acid - unii:xf417d3psl), sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (phosphate ion - unii:nk08v8k8hr), anhydrous dextrose (unii: 5sl0g7r0ok) (anhydrous dextrose - unii:5sl0g7r0ok) - anhydrous citric acid 32.7 mg in 1 ml - for use with haemonetics apheresis devices rx only the haemonetics 250ml anticoagulant citrate phosphate double dextrose (cp2d) and 250ml additive solution formula 3 (as-3) nutrient solution are intended to be used only with automated apheresis devices for collecting human blood and blood components. the anticoagulant solution is metered by the apheresis machine into the collected whole blood. it is not to be infused directly into the donor. after the anticoagulant is used, the bag in which it was contained is discarded. when collecting plasma in the rbcp protocol, the plasma is collected into an empty plasma collection bag. one hundred milliliters (100ml) of as-3 is transferred into one rbc collection bag when using the rbcp protocol or 2 separate bags when using the

United States - English - NLM (National Library of Medicine)

citra labs llc - trisodium citrate dihydrate (unii: b22547b95k) (anhydrous citric acid - unii:xf417d3psl) - anhydrous citric acid 14 g in 30 ml - tricitrasol ® anticoagulant sodium citrate concentrate, 46.7% trisodium citrate, is an anticoagulant used in granulocytapheresis procedures (granulocyte collection by apheresis). just prior to performing granulocytapheresis, aseptically add 30 ml of tricitrasol ® to 500 ml of the 6% solution of hydroxyethyl starch (hes), e.g. hespan ® 2-8 . agitate the resultant solution for 1 minute to assure a uniform concentration of anticoagulant. the resultant solution of tricitrasol ® and 6% solution of hes contains the following concentration depending upon the volume used: the tricitrasol ® /hes solution is stable for up to 24 hours at room temperature after mixing. refer to the manufacturer's operator's manual of the apheresis medical device for the directions to perform the granulocytapheresis procedure. not for direct intravenous infusion.

Malta - English - Medicines Authority

bayer limited 1st floor the grange offices the grange brewery road stillorgan co. dublin, a94 h2k7 , ireland - citric acid, acetylsalicylic acid, sodium hydrogen, carbonate - effervescent tablet - acetylsalicylic acid 324 mg citric acid 965 mg sodium hydrogen carbonate 1744 mg - analgesics

Namibia - English - Namibia Medicines Regulatory Council

adcock-ingram critical care - acid sodium phosphate dihydrate 0.251 g; ; citric acid 0.327g; ; glucose 2.55 g; ; sodium citrate 2.63 g - blood bag - acid sodium phosphate dihydrate 0.251 g; ; citric acid 0.327g; ; glucose 2.55 g; ; sodium citrate 2.63 g

United States - English - NLM (National Library of Medicine)

westminster pharmaceuticals, llc - sodium citrate, unspecified form (unii: 1q73q2julr) (anhydrous citric acid - unii:xf417d3psl), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium citrate and citric acid oral solution usp is an effective alkalinizing agent. it is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. this product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively. sodium citrate and citric acid oral solution usp is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary ph around the clock, usually without the necessity of a 2 a.m. dose. this product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage.this product is highly palatable, pleasant tasting,and tolerable, even when a administered for long periods. contraindicated in patients with sodium-restr

United States - English - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - sodium picosulfate (unii: lr57574hn8) (deacetylbisacodyl - unii:r09078e41y), magnesium oxide (unii: 3a3u0gi71g) (magnesium cation - unii:t6v3lhy838), anhydrous citric acid (unii: xf417d3psl) (anhydrous citric acid - unii:xf417d3psl) - sodium picosulfate 10 mg in 16.1 g - prepopik® is indicated for cleansing of the colon as a preparation for colonoscopy in adults and pediatric patients 9 years of age and older. prepopik is contraindicated in the following conditions: - patients with severe renal impairment (creatinine clearance less than 30 ml/minute) which may result in accumulation of magnesium [see warnings and precautions (5.4)] - gastrointestinal obstruction or ileus [see warnings and precautions (5.6)] - bowel perforation [see warnings and precautions (5.6)] - toxic colitis or toxic megacolon - gastric retention - hypersensitivity to any of the ingredients in prepopik [see adverse reactions (6.2)] risk summary there are no data with prepopik use in pregnant women to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. in an animal reproduction study, no adverse developmental effects were observed in pregnant rats when sodium picosulfate, magnesium oxide, and anhydrous citric acid were administered orally at doses 1